|
gptkbp:instanceOf
|
gptkb:drug
catechol-O-methyltransferase inhibitor
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N04BX02
|
|
gptkbp:brand
|
gptkb:Stalevo
gptkb:Comtan
|
|
gptkbp:CASNumber
|
130929-57-6
|
|
gptkbp:contraindication
|
hepatic impairment
hypersensitivity to entacapone
|
|
gptkbp:discoveredBy
|
gptkb:Orion_Pharma
|
|
gptkbp:drugInteraction
|
gptkb:levodopa
gptkb:warfarin
|
|
gptkbp:eliminationHalfLife
|
0.4–0.7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C14H15N3O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
entacapone
|
|
gptkbp:KEGGID
|
D07913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits catechol-O-methyltransferase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
CHEMBL1425
4445392
5281081
DB00494
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
hallucination
dyskinesia
urine discoloration
|
|
gptkbp:synonym
|
(E)-2-cyano-N,N-diethyl-3,4-dihydroxy-5-nitrobenzenepropenamide
|
|
gptkbp:UNII
|
49717AWG6K
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
|
|
gptkbp:bfsParent
|
gptkb:Comtan
|
|
gptkbp:bfsLayer
|
6
|